Core Viewpoint - The company has received a medical device registration certificate for its fully automated chemiluminescence immunoassay analyzer, indicating a significant advancement in its product offerings in the medical device sector [1] Group 1: Product Details - The product is named MAGLUMI X10 and is classified as a Class II medical device [1] - The registration certificate number is 粤械注准20252220811, with a validity period from June 10, 2025, to June 9, 2030 [1] - The analyzer utilizes a direct chemiluminescence method based on luminol derivatives, designed for qualitative or quantitative detection of analytes in human-derived samples such as serum, plasma, urine, and whole blood [1]

证券代码：300832 证券简称：新产业 公告编号：2025-048 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 1 产品名称 及型号 注册 分类 注册证编号 注册证有效期 适用范围 全自动化学发光 免疫分析仪（型 号：MAGLUMI X10） II类 粤械注准 20252220811 2025 年 06 月 10 日至 2030 年 06 月 09 日 该产品采用基于异鲁米诺衍 生物的直接化学发光法，与配 套的检测试剂共同使用，在临 床上用于对来源于人体的血 清、血浆、尿液和全血样本中 的被分析物进行定性或定量 检测，包括激素、肿瘤相关抗 原、蛋白质及多肽、肝病、心 肌疾病、免疫功能、自身抗体、 感染性疾病、维生素与血药浓 度、其它酶类、出凝血、人尿 微量白蛋白、人免疫球蛋白E、 降钙素原。 一、医疗器械注册证的具体情况 取得《医疗器械注册证》，涵盖肿瘤标志物、甲状腺、传染病、心血管及心肌 标志物等大类，可以满足临床日常化学发光检验需求。上述医疗器械注册证的 取得，丰富了公司化学发光免疫分析仪器产品线，将对公司发展具有正面影响， 但对近期的生产经营和业绩不会产生重大影响，敬请投资者给 ...

Group 1 - Medical device sector shows strong performance with ETF fund (159797) experiencing significant trading volume and net inflow of funds [1] - Recent policy document issued on June 9 aims to improve healthcare resources and insurance mechanisms, which is seen as a major driver for pharmaceutical companies [3] - Citic Securities predicts a trend of low-to-high earnings growth in the medical device sector, with significant improvements expected in the second half of the year [4] Group 2 - Structural investment opportunities exist within the medical device sector, with certain companies expected to achieve high growth in Q2 and Q3 [5] - The easing of US-China tariffs is beneficial for medical device companies, potentially lowering production costs and expanding overseas market share [6] - The medical device ETF fund (159797) covers core areas such as medical equipment and in vitro diagnostics, with top ten weighted stocks accounting for 46.78% [6][7]

Core Viewpoint - The intelligentization of coal mines is a core technological support for the high-quality development of the coal industry and is essential for the industry's transformation and upgrading [1][2] Group 1: Intelligent Mining Development - The Chinese Coal Science and Technology Group is actively responding to national demands by leading the "Unmanned Intelligent Mining Technology and Engineering Application" project, focusing on overcoming technical bottlenecks in unmanned mining [1][3] - By 2025, the goal is to achieve minimal or no human operation in coal mining work faces, with significant advancements made in remote intervention models over the past five years [2][3] Group 2: Innovation and Collaboration - The company has launched a project to develop an unmanned mining control system, inviting teams to tackle challenges in unmanned coal mining, resulting in the identification of 31 key challenges and 89 tasks [3][4] - Collaborations with top universities and research institutions are ongoing to integrate cutting-edge technologies such as IoT, big data, and AI into the unmanned mining control technology [4][5] Group 3: Technological Infrastructure - The company has established nine specialized laboratories and a remote intelligent service platform for unmanned mining, covering over 2,500 square meters and valued at over 32 million yuan [5][6] - The company has been recognized for its contributions to the development of intelligent mining, providing technical support for 55% of the first batch of national intelligent demonstration mines [6][7] Group 4: Smart Manufacturing - The intelligent mining equipment production base has achieved full automation and intelligence in production processes, significantly enhancing production efficiency and energy conservation [7][8] - The base has been recognized as a digital transformation pilot enterprise and an intelligent manufacturing demonstration factory, receiving multiple honors for its achievements [8]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

证券代码：300832 证券简称：新产业 公告编号：2025-047 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 国家知识产权局颁发的1项《发明专利证书》，现将本次取得的发明专利具体情 况公告如下： 发明名称：抗PIC的抗体、试剂盒及检测PIC的方法 中国专利号：ZL202210547227.2 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：张云、高莉、甘兴、万谦、王燕梅、赵莉 专利申请日：2022年05月19日 授权公告日：2025年05月27日 上述专利保护技术为公司自主研发，本发明提供了一种新的抗纤溶酶-α2纤 溶酶抑制剂复合物（PIC）的抗体，该抗体对PIC抗原的亲和力和特异性更高，因 而利用该抗体进行双抗体夹心法检测样品时，能够实现一步法检测，在特异性和 准确性高的同时，大大缩短了检测时间，提高了检测速度和效率。 本次取得的发明专利不会对公司目前的经营状况产生重大影响，但有利于完 善公司知识产权体系， ...

Group 1 - The core point of the news is that 华夏基金管理有限公司 is convening a communication-based meeting for the fund holders of 华夏新锦升灵活配置混合型证券投资基金 to discuss the proposal for the fund's continued operation due to its net asset value falling below 50 million yuan for 60 consecutive working days [37][38]. - The meeting will be held via communication, and the voting period is from June 11, 2025, to July 8, 2025, with the counting date set for July 9, 2025 [3][5][28]. - Fund holders must register their rights by June 10, 2025, to participate in the voting process [5]. Group 2 - The proposal includes authorizing the fund manager to handle specific matters related to the fund's continued operation, including determining the timing and measures for the fund's ongoing operations based on market conditions [37][38]. - Fund holders can vote directly or authorize others to vote on their behalf, with specific requirements for both individual and institutional holders [10][11][19]. - The voting rights are calculated based on the number of fund shares held on the registration date, with each share representing one vote [29][31].

Core Viewpoint - Shenzhen is positioning itself as a leader in the new track of "new quality productivity," focusing on hard technology innovations such as artificial intelligence, drones, and new energy vehicles, which are crucial for the global industrial landscape transformation [1][3]. Group 1: Technological Advancements - Shenzhen's R&D investment reached 223.66 billion yuan, growing by 18.9%, marking nine consecutive years of double-digit growth, which supports breakthroughs in hard technology [3]. - Major technological showcases at recent exhibitions included BYD's "megawatt flash charging" technology, allowing for a one-minute charge to achieve a 100-kilometer range, addressing user concerns about range anxiety [3]. - Huawei unveiled significant products like the HUAWEI MateBook Fold and HUAWEI MateBook Pro at the global AI terminal exhibition, while DJI showcased the new Matrice 4 series drones with advanced AI detection capabilities [4]. Group 2: Application of Technology - The trend of technology rapidly transitioning from exhibition to real-life applications is evident, with AI and drones being integrated into various sectors such as smart homes, logistics, and emergency services [5][6]. - Shenzhen plans to open 100 application scenarios annually to enhance the matching of supply and demand, facilitating product development and technology iteration [6]. Group 3: Ecosystem Development - The exhibitions reflect a shift from merely showcasing products to presenting an entire ecosystem, highlighting the collaboration between technology and industry [7]. - The establishment of the Shenzhen AI Glasses Industry Alliance aims to integrate resources across the AI glasses sector, promoting innovation and scaling [8][9]. - Policies supporting the development of these industries include the launch of investment funds for AI terminals and robotics, indicating a strong commitment to fostering long-term capital investment [9]. Group 4: Future Outlook - The combination of hard technology breakthroughs, accelerated application scenarios, and efficient industrial ecosystem collaboration forms the "innovation triangle," which is central to Shenzhen's new quality productivity strategy [9].

Core Insights - The article discusses the evolution and current state of intellectual property asset-backed securities (ABS) in China, highlighting its significance in financing for small and medium-sized technology enterprises [1][2][10] - It emphasizes the growth of the market, with a cumulative issuance scale exceeding 200 billion yuan by June 2025, and the increasing recognition of intellectual property as a valuable asset [1][10] Market Development - The first intellectual property ABS in China was approved in December 2018, and as of June 5, 2023, at least 12 intellectual property ABS have been issued this year, totaling 1.356 billion yuan [1] - In 2024, the issuance of intellectual property ABS products reached 57, with a total scale of 9.806 billion yuan, marking a year-on-year increase of 25.97% [2] Institutional Concentration - The majority of intellectual property ABS issuers are small loan companies, commercial factoring companies, and financing leasing companies, with a high concentration among the top five issuers, accounting for 74.68% of the total issuance [2][4] - Shenzhen's small loan companies dominate the market, with Shenzhen Zhongxiaodang and Shenzhen Gaoxin Investment holding a combined market share of 58.80% [2][4] Product Characteristics - Intellectual property ABS typically have smaller issuance sizes, around 100 million yuan, and primarily serve smaller enterprises, reflecting a certain degree of inclusive finance [4][8] - The underlying asset types for intellectual property ABS are diversifying, including agricultural IP, new energy vehicle IP, and digital currency IP [5] Financing Channels - The article highlights the exploration of cross-border financing channels for intellectual property ABS, particularly in the Greater Bay Area, allowing companies to leverage their intellectual property for overseas financing [5][6] Operational Standards - The operational model for intellectual property ABS has become more standardized, with established processes for small loan companies to provide funding and guarantee enhancements [7][8] - The Shenzhen model of intellectual property ABS is characterized by state-owned enterprises leading the initiative, government subsidies reducing financing costs, and active market participation [10][12] Market Challenges - Despite the growth, the intellectual property ABS market is still in its early stages, with limited investor recognition and liquidity issues affecting issuance and trading [13][14] - Challenges include the lack of unified standards for intellectual property valuation and the need for improved risk management practices [14][15]

Core Viewpoint - The Guangzhou Marine Technology Innovation Industry Development Conference aims to accelerate the development of marine new productivity and establish Guangzhou as a hub for marine innovation and development [2][3]. Group 1: Government Initiatives - Guangzhou is focusing on building a modern industrial system characterized by the "12218" framework, emphasizing sectors such as ports, shipping, energy, pharmaceuticals, and tourism [2]. - The government plans to optimize the business environment and implement marine industry planning, investment policies, and resource guarantees to attract entrepreneurs and scientists [2][3]. Group 2: Strategic Collaborations - The conference featured the launch of the first national marine government-industry-research-academia exchange platform, "Guanghaihui," and strategic cooperation agreements were signed with various institutions [3]. - The event showcased 20 cutting-edge marine technology innovations, highlighting Guangzhou's commitment to marine economic development and investment promotion [3]. Group 3: Economic Potential - Guangzhou's marine industry is comprehensive, with a leading position in marine economic output and technological innovation capabilities, which are seen as unique advantages for driving marine technology and industry development [3].